Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKesson
Baxter
Merck
Harvard Business School

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Sciele Pharma Inc. v. Lupin Ltd. (D. Del. 2009)

See Plans and Pricing

« Back to Dashboard

Sciele Pharma Inc. v. Lupin Ltd. (D. Del. 2009)

Docket   Start Trial Date Filed 2009-01-15
Court District Court, D. Delaware Date Terminated 2013-06-13
Cause 35:271 Patent Infringement Assigned To Robert B. Kugler
Jury Demand Defendant Referred To Joel Schneider
Parties ANDRX CORPORATION; ANDRX EU LTD.; ANDRX LABORATORIES (NJ) INC.; ANDRX LABS LLC; ANDRX PHARMACEUTICALS INC.; ANDRX PHARMACEUTICALS LLC; LUPIN LTD.; LUPIN PHARMACEUTICALS INC.; MYLAN INC.; MYLAN PHARMACEUTICALS INC.; SCIELE PHARMA INC.; SHIONOGI PHARMA INC.
Patents 10,066,017; 6,099,859; 6,495,162; 6,790,459; 6,866,866; 6,958,161; 7,919,116
Attorneys D. Christopher Ohly; David A. Manspeizer; David B. Bassett; David Ellis Moore; Erica S. Helms; Frederick L. Cottrell , III; Gary E. Hood; Jack B. Blumenfeld; Jason James Rawnsley; Jennifer Ying; Julia Heaney; Karen A. Confoy; Karen Jacobs; Kathryn S. Devine; Mary Matterer; Melanie R. Rupert; Richard D. Kirk; Richard L. Horwitz; Robyn H. Ast-Gmoser; Stephen B. Brauerman; Steven J. Fineman
Firms Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Sciele Pharma Inc. v. Lupin Ltd.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Sciele Pharma Inc. v. Lupin Ltd.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Sciele Pharma Inc. v. Lupin Ltd. (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2009-03-19 21 United States Patents No. 6,495,162 (“the ‘ 162 Patent”) and 6,790,459 (“'the ‘459 Patent”). For reasons…United States Patent No.s 6,099,859 (“the ‘859 Patent”), and 6,866,866 (“the ‘866 Patent”), both of which…Delaware had 157 new patent cases filed, 112 patent cases terrninated, and 268 patent cases pending. ln …, there were 25 new patent cases filed, 26 patent cases terrninated, and 27 patent cases pending See Exhibit… ‘866 patents. It also states causes of action relating to two other Orange Book listed patents that relate External link to document
2011-12-14 289 Exhibit A hyclate. Mayne also owns U.S. Patent No. 6,958,161 (“the ’161 Patent”), entitled “Modified Release…MYLAN PHARMA Mayne licenses the ’161 Patent to Plaintiffs-Appellees Warner Chilcott…A)(vii)(IV) asserting that the ’161 Patent is invalid, unenforceable, and/or will …this appeal is claim 21 of the ’161 Patent, which recites: A tablet for oral…- tion profile. ’161 Patent col. 14 ll.20-23 (emphasis added). External link to document
2012-01-03 299 20:16, 20:18, 24:6, 28:6, 28:7, 28:10, 66:17, 67:2, 69:2, 61:3 … on a patent that 22 the patent examiners did not intend to be in this patent. … as to the patent and whether or not 21 they're violating the patent. They… 9 of the asserted patent. So we have focused on the 866 Patent. 00:57 10 … of our patent claims by clear and convincing 01:12 25 evidence. The 866 Patent is entitled External link to document
2012-01-31 313 Delaware. PATENTS IN SUIT 18. Andrx is the owner of United States Patent No. 6,099,859 (“the ‘859 patent… LUPIN AND LUPIN PHARMA OF UNITED STATES PATENT NO. 6.099,859 30. Plaintiffs reallege paragraphs 1-29… 35 U.S.C. § 271(a)-(C) OF UNITED STATES PATENT NO. 6.099,859 42. Plaintiffs reallege paragraphs 1- 41… license under the ‘859 patent in the United States. A copy of the ‘859 patent is attached as Exhibit …Andrx is the owner of United States Patent No. 6,866,866 (“the ‘866 patent”), which was duly and legally issued External link to document
2012-02-07 322 The term “patents-in-suit” refers to U.S. Patent Nos. 6,099,859 (the “‘859 Patent”) and 6,866,866…HCl ER Tablets (500 and 1000 mg) U.S. Patents Nos. 6,099,859, 6,495,162, 6,790,459, and 6,866,866 Notice…866 Patents, the circumstances through which they first learned of the ‘859 and/or ‘866 Patents, and…analysis of the ‘859 and/or ‘866 Patents. 17. Any patent policy in effect at Lupin at any… “Lupin’s Paragraph IV Certification” means the patent certification filed by Lupin with the FDA pursuant External link to document
2012-02-07 323 The term “patents-in-suit” refers to U.S. Patent Nos. 6,099,859 (the “‘859 Patent”) and 6,866,866…regarding “Paragraph IV Patent Certification Notice – U.S. Patents [sic] Nos. 6,099,859, 6,495,162, 6,790,459…866 Patents, the circumstances through which they first learned of the ‘859 and/or ‘866 patents. … “Mylan’s Paragraph IV Certification” means the patent certification filed by Mylan with the FDA pursuant…,866 (the “‘866 Patent”). TOPICS OF EXAMINATION 1. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKinsey
Express Scripts
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.